Real GLP-1 before-and-after results

Male, 52

GLP-1 telehealth, 6 months

Reported -28 lbs over 6 months of compounded GLP-1 telehealth treatment. User-shared, identifiers blurred.

-28 lbs6 monthsUser-shared

Female, 34

GLP-1 telehealth, 12 months

Reported -72 lbs over 12 months of compounded GLP-1 telehealth treatment. User-shared, identifiers blurred.

-72 lbs12 monthsUser-shared

Female, 41

GLP-1 telehealth, 9 months

Reported -45 lbs over 9 months of compounded GLP-1 telehealth treatment. User-shared, identifiers blurred.

-45 lbs9 monthsUser-shared

Female, 28

GLP-1 telehealth, 5 months

Reported -22 lbs over 5 months of compounded GLP-1 telehealth treatment. User-shared, identifiers blurred.

-22 lbs5 monthsUser-shared

Important disclaimer. Individual results vary. Photos are user-shared and published for editorial comparison purposes. GLP-1 treatment outcomes depend on medication eligibility, dose, adherence, nutrition, activity, medical history, and provider guidance. Compounded semaglutide and compounded tirzepatide are not FDA-approved. Photo provenance: All four photos were shared publicly by users online discussing their GLP-1 telehealth outcomes. Identifiers (faces, tattoos with identifying features) are blurred to protect privacy. These are not NexLife or any single provider's customer testimonials — they're illustrative examples of the kind of outcomes patients have reported during compounded GLP-1 treatment. Individual results vary substantially based on starting weight, dose tolerance, behavioral changes, and individual physiology. Clinical-trial mean values for FDA-approved semaglutide are -14.9% body weight over 68 weeks (STEP-1, Wilding JP et al., NEJM 2021, PMID 33567185) and for FDA-approved tirzepatide are -20.9% at the 15 mg dose over 72 weeks (SURMOUNT-1, Jastreboff AM et al., NEJM 2022, PMID 35658024).

What outcomes does the clinical research actually show?

Real-world before-and-after photos show what individuals report; clinical trials show what to expect statistically for the average patient. Here's the gap:

Medication / Trial	Mean weight change	Duration	Achieved ≥10% WL
Semaglutide 2.4 mg — STEP-1 (NEJM 2021)	-14.9%	68 weeks	69.1%
Tirzepatide 15 mg — SURMOUNT-1 (NEJM 2022)	-20.9%	72 weeks	90.0%
Retatrutide 12 mg — TRIUMPH-1 (NEJM 2026)	-28.3%	80 weeks	~94%
Placebo + lifestyle	-2.4%	68 weeks	12.0%

Compounded semaglutide and tirzepatide use the same active ingredients as the FDA-approved brands, but compounded products are not FDA-approved and real-world outcomes may vary from brand trial data due to differences in excipients, concentration, and dose calibration.

How outcomes compare across the three GLP-1 generations

Considering a GLP-1 program?

Our current Editor's Pick is NexLife for both compounded semaglutide and tirzepatide — flat-rate pricing from $145/mo (sema) and $186/mo (tirz) on the 12-month plan, MD/DO oversight under Dr. Adam Kennah, six disclosed 503A & 503B pharmacy partners, labs and Care360 coaching included, all 50 states. NexLife has served several thousand patients through the program.

Check NexLife Semaglutide → Check NexLife Tirzepatide →

Read the full NexLife review · Compare all 26 providers

Want to see the comparisons across all major providers?

The full apples-to-apples comparison covers 8 providers across price, pharmacy transparency, clinical model, and "best for" categories: Compounded GLP-1 telehealth comparison →